Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,839 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT05874063RecruitingPhase 3
Preventing blood clots during first chemotherapy for germ cell tumors
This Phase 3 study tests whether giving enoxaparin (a blood thinner) can prevent dangerous blood clots in people with advanced germ cell tumors starting their first chemotherapy. It is especially focused on people who are at higher risk of clots.
AngersAges 18 years+ - NCT06938321RecruitingPhase 1/Phase 2
New drug combo for advanced bile duct and gallbladder cancer
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06940180RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for sinus cancer
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
Boston, MassachusettsAges 18 years+ - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06927635RecruitingPhase 2
SBRT vs standard care for prostate cancer that has spread to a few spots
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Toronto, OntarioAges 18–100 - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+ - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06922383RecruitingPhase 1/Phase 2
Study of arfolitixorin in advanced colorectal cancer
This study tests a new drug called arfolitixorin given with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy for people with advanced colorectal cancer that has spread. It may help the chemotherapy work better.
BerlinAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06911970Recruiting
Exercise and immune response in cancer treatment
This trial tests whether aerobic exercise can help your immune system fight cancer better during chemotherapy or immunotherapy. It is for people with breast or colon cancer that has not spread to other parts of the body.
Sherbrooke, QuebecAges 40–70 - NCT06912087RecruitingPhase 1
Finding the right dose of a new combo for head and neck cancer
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
Chicago, IllinoisAges 18 years+ - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT06061705Recruiting
Finding markers in patients with head and neck cancer on immunotherapy
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
ParisAges 18 years+ - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06114004RecruitingPhase 2
Selinexor plus gemcitabine for advanced soft-tissue sarcoma
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
Santa Cruz de Tenerife, Canary IslandsAges 18–80
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,839 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.